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Abstract: Lung cancer is the leading cause of cancer-related death in many countries. Approximately half of the patients with   non-small 
cell lung cancer have advanced disease and systemic chemotherapy, especially platinum-based doublets, is currently the standard 
  treatment. Several trials have recently indicated the importance of histological subtype for treatment with molecular target   chemotherapy 
and pemetrexed. Over the last decade, gemcitabine, a pyrimidine nucleoside antimetabolite, has been one of the most effective agents 
for patients with advanced non-small cell lung cancer. It is unknown whether histological type is a predictor of the outcome of treatment 
with this agent. This is a review of the past trials and reviews of first-line treatment for advanced NSCLC, focusing on efficacy and 
safety of treatment with gemcitabine according to histological subtype.
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Overview
Lung cancer is the leading cause of cancer-related death 
in many countries. The disease can be classified into 
two types, non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC), with NSCLC account-
ing for 80%–85% of all cases. Approximately half of the 
patients with NSCLC have advanced disease. The stan-
dard therapy for patients with good performance status 
(PS) is systemic chemotherapy. Based on the results of 
a meta-analysis, cisplatin (CDDP)-based doublets are 
considered the best available therapy for patients with 
metastatic NSCLC, because of the moderate improve-
ment in survival. 1 Several new agents with significant 
activity against NSCLC, such as paclitaxel, docetaxel, 
vinorelbine, and gemcitabine, have been introduced and 
any of these agents used in combination with a platinum 
agent was shown to improve the outcome compared 
to older agents2 and each regimen provided a similar 
survival outcome.3,4 Unfortunately, the tumor recurs in 
almost all patients. Relapsed patients who still have a 
good PS receive second-line chemotherapy, which is 
considered a standard of care. Docetaxel, pemetrexed, 
and epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs), including erlotinib and gefi-
tinib, are used in this setting.
Gemcitabine  (2’,2’-difluoro  2’-deoxycytidine, 
dFdC) is an analogue of Ara-C from which it struc-
turally differs due to fluorine substituents on posi-
tion 2’ of the furanose ring.5 Despite structural and 
pharmacological  similarities  to  Ara-C,  gemcit-
abine  displays  distinctive  characteristics  of  cellu-
lar   pharmacology.6 In in vitro and phase I studies, 
gemcitabine has shown activity against many kinds 
of  tumors,  especially  NSCLC.7–10  The  evidence  of 
its potent antitumor activity in a wide spectrum of 
tumor  models  has  been  successfully  confirmed  in 
clinical practice. Today gemcitabine is indicated for 
patients with pancreatic cancer, bladder cancer, breast 
cancer, malignant mesothelioma, and ovarian cancer 
besides those with NSCLC. Several early phase II 
studies of single-agent gemcitabine were performed 
in chemonaïve patients with advanced NSCLC uti-
lizing the weekly schedule (days 1, 8 and 15) with a 
30-minute infusion, repeated every four weeks at a 
dose of 800–1,250 mg/m2. Objective response rate of 
20%–25% and a median survival of 9 months were 
observed. Moreover, phase II trials with gemcitabine 
plus CDDP   demonstrated that response rates of 40% 
to above 50% were favorable.11,12 These findings lead 
to phase III trials, in which superiority of gemcitabine 
plus CDDP for chemonaïve patients with advanced 
NSCLC in terms of both overall survival (OS) and 
quality of life benefit when compared with platinum 
alone or in combination with etoposide.13,14 There-
fore, gemcitabine/CDDP is widely used in clinical 
practice all over the world, and in several countries 
has become a most popular combination regimen for 
the treatment of advanced NSCLC.
More recently, some molecular targeted agents 
have been developed for the treatment of NSCLC. 
A large, randomized phase III study showed clear 
efficacy  by  adding  bevacizumab,  which  inhibits 
vascular endothelial growth factor (VEGF), to the 
combination  platinum  based  chemotherapy.15,16 
In addition, EGFR-TKIs were very effective in a 
special molecularly defined population of patients 
harboring  EGFR  somatic  mutations.17,18  In  this 
way, much interest is concentrated on the devel-
opment of molecular target agents and of person-
alized  treatment  on  the  basis  of  their  molecular 
characteristics.
On the other hand, tumor histology has not been 
recognized  as  a  consistent  prognostic  factor  in 
patients with NSCLC so far.19 Recently, a preplanned 
subset analysis by histology in a large phase III trial 
demonstrated longer survival for pemetrexed/CDDP-
treated than for gemcitabine/CDDP-treated patients 
with non-squamous NSCLC histology, while patients 
with  squamous  cell  carcinoma  treated  with  peme-
trexed/CDDP had a shorter survival than those treated 
with  gemcitabine/CDDP.20  This  finding    indicated 
that histology could serve as a predictor of the out-
come of NSCLC patients treated with pemetrexed. 
However, it is unknown whether histology serves as 
a predictor for patients treated with other cytotoxic   
chemotherapies.
Here we will briefly review the role of gemcitabine 
as a treatment option for NSCLC, especially focusing 
on histological subtypes. Association of efficacy or 
safety with histological subtype will be discussed in 
the whole population and elderly patients.
Gemcitabine Combined with a 
Platinum Agent as First-Line Treatment
In the ECOG 1594 trial, the combination of gemcit-
abine plus CDDP was compared to other   standard Review of gemcitabine efficacy in advanced NSCLC: subgroup of histology
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doublets. This phase III trial   demonstrated   equivalent 
response rates among the three   experimental arms, 
including docetaxel/CDDP, paclitaxel/CBDCA and 
gemcitabine/CDDP,  compared  with  the  control 
arm of paclitaxel/CDDP. In the groups of patients 
assigned to a regimen of gemcitabine/CDDP, gemcit-
abine at a dose of 1000 mg/m2, was administered on 
days 1, 8, and 15 and CDDP, at a dose of 100 mg/m2, 
was administered on day 1 of a four-week cycle. 
The median time to progression in the gemcitabine/
CDDP group was 4.2 months and significantly better 
compared with that of the control arm, which was 
3.4 months. Although there were no significant dif-
ferences in the response rate or OS among the three 
experimental-treatment  groups,  there  was  a  trend 
for an improvement of the 1 and 2-year survival 
in the gemcitabine/CDDP arm. Moreover, a meta-
analysis was performed to evaluate the treatment 
effect of gemcitabine plus a platinum agent, either 
CDDP or CBDCA, on advanced NSCLC.21 Thirteen 
trials that met the inclusion criteria were selected if 
there was a comparison between gemcitabine plus 
platinum with any non-gemcitabine platinum-con-
taining regimen. The protocol for the meta-analysis 
was finalized in August 2002 and individual patient 
data  were  obtained  from  the  principal  investiga-
tors for seven of the 13 trials. Overall, the median 
OS  was  9.0  months  for  the  gemcitabine-based 
treatment arms and 8.2 months for the compara-
tor group and the estimated pooled HR for OS was 
0.90 (95% CI: 0.84–0.96, P , 0.001) in favor of 
gemcitabine based   regimens. Comparing the first- 
and second generation platinum-based comparator 
regimens, the HR was 0.84 showing a significant 
gain with gemcitabine-based regimens, while the 
differences were not significant when compared to 
the third-  generation agent comparators. There was 
an also significant decrease in the risk of disease 
progression in favor of   gemcitabine-platinum regi-
mens, HR 0.88 (95% CI: 0.82–0.93, P , 0.001). 
Sub-group  analysis  indicated  a  significant  PFS 
benefit for patients assigned to gemcitabine-plati-
num treatment even compared to third-generation 
agent plus platinum regimens. Thereafter,   several 
trials  which  aimed  to  quantify  the  treatment 
effect of gemcitabine plus a   platinum agent were 
  performed,  however,  none  of  the  trials  showed 
a significant improvement of OS.
Efficacy of Gemcitabine-Platinum 
Chemotherapy by Histological Subtype
In  ECOG  1594,  a  subgroup  analysis  to  compare 
the  efficacy  in  different  histological  subtypes  was 
also conducted.22 Of 1139 eligible patients, adeno-
carcinoma was the most common histological type 
(n = 647; 56.8%), followed by squamous cell car-
cinoma (n = 224; 19.7%) and large cell carcinoma 
(n = 74; 6.5%). Not otherwise specified (NOS) cases 
were also included in this trial (n = 194; 17.0%). No 
difference in OS and PFS was observed among the 
four  histological  subtypes,  regardless  of  treatment 
arm. There were no survival differences either among 
the four regimens of chemotherapy in each histologi-
cal subtype (Table 1). In the squamous cell carcinoma 
and large cell carcinoma subgroups, patients treated 
with gemcitabine/CDDP appeared to have a longer 
OS compared to other regimens, while patients with 
adenocarcinoma in the paclitaxel/CDDP arm showed 
a better survival, although the difference was not sta-
tistically significant.
Other  retrospective  analyses  of  three-arm  ran-
domized trials comparing paclitaxel/CBDCA, gem-
citabine/CDDP, and vinorelbine/CDDP explored the 
potential predictive and prognostic role of   histology.23 
Pairwise comparisons of histological subtypes dem-
onstrated a survival advantage for squamous cell car-
cinoma over adenocarcinoma (P = 0.0021), however, 
histology was not predictive of treatment effect for 
either OS or time to progression.
Other  investigators  assessed  the  literature  on 
NSCLC of the last 25 years with a special emphasis 
on an association between histological subtype, and 
the efficacy of a specific chemotherapeutic agent.19 
Of 408 publications identified, 11 reported a prog-
nostic  association  between  histology  and  clinical 
outcome, showing a relationship between more dif-
ferentiated histology and better clinical outcome, and 
a prolonged survival of patients with adenocarcinoma 
or carcinomas other than squamous-cell carcinoma. 
Moreover, 7 studies suggested that histological sub-
type was a predictor of outcome in patients treated 
with  specific  cytotoxic  chemotherapy  regimens. 
However, the limitation of this analysis is that those 
data are derived from either an unplanned subset or 
retrospective analyses not aimed to examine the role 
of histology. Therefore, no clear conclusions could be 
drawn.Hayashi et al
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More  recently,  several  trials  have  prompted  a 
renewed interest in the impact of NSCLC histologi-
cal subtype on efficacy outcomes. Especially, pem-
etrexed and bevacizumab containing regimens might 
have a greater impact on adenocarcinoma. Four trials 
identified a relation between pemetrexed treatment 
and histology, showing a better outcome in patients 
with non-squamous cell carcinoma.20,24–26
Of these trials, a pivotal phase III trial compar-
ing gemcitabine/CDDP with pemetrexed/CDDP in 
1725  chemotherapy-naïve  patients  with  advanced 
NSCLC was the first to prospectively assess sur-
vival differences according to histology (Table 2).20 
Patients were assigned to receive CDDP 75 mg/m2 
on day 1 plus gemcitabine 1250 mg/m2 on days 1 and 
8 or CDDP 75 mg/m2 and pemetrexed 500 mg/m2 
on day 1 every 3 weeks, for up to 6 cycles. OS for 
pemetrexed/CDDP was noninferior to gemcitabine/
CDDP (10.3 months for both arms: HR: 0.94; 95% 
CI: 0.84–1.05) and PFS was 4.8 months for the pem-
etrexed/CDDP,  whereas  PFS  was  5.1  months  for 
gemcitabine/CDDP (HR: 1.04 95% CI: 0.94–1.15). 
Response rates were subequal for the two arms (gem-
citabine/CDDP: 28.2%, pemetrexed/CDDP: 30.6%). 
With respect to toxicity, for pemetrexed/CDDP, rates 
of grade 3–4   neutropenia, anemia, thrombocytopenia 
(P , 0.001), febrile   neutropenia (P = 0.002) and alo-
pecia (P , 0.001) were significantly lower, whereas 
the rate of grade 3–4 nausea (P = 0.004) was higher. 
This trial also demonstrated different effects on sur-
vival of pemetrexed/CDDP against non-squamous 
(adenocarcinoma and large-cell carcinoma) versus 
squamous histology. Patients with adenocarcinoma 
(n = 847) and large-cell carcinoma (n = 153) treated 
with  pemetrexed/CDDP  showed  a    significantly 
better  survival  compared  with  those  treated 
with    gemcitabine/CDDP  (12.6  vs.  10.9  months; 
HR: 0.84; 95% CI: 0.71–0.99; P = 0.03; 10.4 vs. 
6.7 months, HR: 0.67; 95% CI: 0.48–0.96; P = 0.03, 
respectively). On the other hand, in patients with 
squamous cell histology, survival with   pemetrexed/
CDDP  was  inferior  than  with  gemcitabine/CDDP 
([n = 473]: 9.4 vs. 10.8 months; HR: 1.23; 95% CI: 
1.00–1.51; P = 0.05). The OS for NOS (n = 252) did 
not show a significant difference in survival between 
the two arms (8.6 vs. 9.2 months; HR: 1.08; 95% 
CI: 0.81–1.45; P = 0.586). Considering histology 
of non-squamous cell carcinoma (adenocarcinoma 
and large cell carcinoma, n = 1252),   pemetrexed/
CDDP showed a significantly longer survival (11.0 
vs.  10.1  months;  HR:0.84;  95%  CI:  0.74–0.96; 
P = 0.011). Same survival difference according to 
histology has been found in three other trials per-
formed  with  pemetrexed  in  advanced  NSCLC  in 
different settings.
On  the  other  hand,  two  phase  III  trials  which 
  evaluated the effects of the angiogenesis inhibitor, bev-
acizumab, were conducted in patients with advanced 
Table 1. Overall survival of histology subgroups in eCOG 1594. 
Chemotherapy Adenocarcinoma Squamous-cell  
carcinoma
Large-cell  
carcinoma
Others P value
n = 194 n = 647
n = 224 n = 74
OS  
(months)
Gemcitabine/CDDP 8.1 9.4 9.7 7.9 0.63
Paclitaxel/CDDP 9.1 6.9 6.1 6.0 0.09
Docetaxel/CDDP 7.7 8.1 6.8 8.2 0.91
Paclitaxel/CBDCA 7.6 9.3 8.3 6.9 0.37
P value 0.39 0.18 0.39 0.82
Table 2. Median overall survival (OS) and progression-free survival (PFS) for the patients with nonsquamous histology 
(adenocarcinoma plus large-cell) and patients with squamous-cell histology. HR, hazard ratio.
Non squamous-cell carcinoma Squamous-cell carcinoma
PFS (months) OS (months) PFS (months) OS (months)
Gemcitabine/CDDP 4.7 10.4 5.5 10.8
Pemetrexed/CDDP 5.3 11.8 4.4 9.4
HR (95% CI) 0.90 (0.79–1.02) 0.81 (0.70–0.94) 1.36 (1.12–1.65) 1.23 (1.00–1.51)Review of gemcitabine efficacy in advanced NSCLC: subgroup of histology
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NSCLC and showed a difference on the safety profile 
of treatment including bevacizumab by the difference 
of histological subtype. Bevacizumab, a humanized 
monoclonal anti VEGF, has shown clinical activity 
against several types of human cancer.
The use of bevacizumab in patients with squamous 
histology is excluded because of the increased risk of 
bleeding, which is potentially fatal for patients with 
squamous lung cancer, as demonstrated in a phase 
II  study.27 Therefore,  ECOG  conducted  a  random-
ized study in which 878 patients with recurrent or 
advanced non-squamous NSCLC were allocated to 
the paclitaxel/CBDCA alone group or to the beva-
cizumab  group.  Patients  with  brain  metastases, 
clinically significant hemoptysis, uncontrolled hyper-
tension, a history of thrombotic or hemorrhagic dis-
orders, therapeutic anticoagulation, inadequate organ 
function or poor PS, were also excluded. The median 
OS of 12.3 months in the reference arm was signifi-
cantly longer than the 10.3 months in the control arm. 
(HR: 0.79; 95% CI: 0.67–0.92; P = 0.003). There was 
also  a  significant  PFS  difference  favoring  patients 
in the bevacizumab arm compared with the control 
arm (6.2 months versus 4.5 months, HR: 0.66; 95% 
CI: 0.57–0.77; P , 0.001).
The gemcitabine, randomized, placebo-controlled, 
phase III study (Avastin in Lung Cancer: AVAiL trial) 
evaluated  the  addition  of  bevacizumab  to  gemcit-
abine/CDDP for advanced NSCLC.15 The primary end 
point was PFS and the eligibility criteria were almost 
similar  to  those  of  the  ECOG4599  trial.  Between 
  February 2005 and August 2006, 1043 patients were 
randomized to receive gemcitabine/CDDP alone every 
3 weeks for six cycles with placebo or with bevaci-
zumab either 7.5 or 15 mg/kg every 3 weeks until dis-
ease progression. Although OS was not significantly 
increased  with  bevacizumab,  the  difference  in  PFS 
was    statistically    significant.  The  median  PFS  were 
6.1, 6.7 and 6.5 months for chemotherapy alone, plus 
bevacizumab 7.5 mg/kg and 15 mg/kg, respectively 
(HR: 0.75; 95% CI: 0.62–0.91; P = 0.003, HR: 0.82; 
95% CI: 0.68–0.98; P = 0.03), while the median OS 
were 13.7, 14.1, and 14.5 months, respectively (HR: 
0.94; 95% CI: 0.78–1.14; P = 0.553, HR: 0.97; 95% CI: 
0.80–1.18; P = 0.75, respectively). The response rate to 
  gemcitabine/CDDP with   bevacizumab was   significantly 
higher than   chemotherapy alone (Table 3).
As of 2011, in advanced NSCLC, bevacizumab 
has  been  approved  only  in  combination  with  car-
boplatin and paclitaxel by the U.S. Food and Drug 
Administration (FDA), whereas the European Medi-
cines Agency has approved it for administration in 
combination with any platinum-based chemotherapy. 
A bevacizumab treatment observational cohort study 
(Avastin Registry: Investigation of Treatment Effects 
and Safety: ARIES) which was conducted in the U.S 
demonstrated that the most used regimen with bevaci-
zumab was paclitaxel/CBDCA in 61.7% patients and 
only about 10% patients received gemcitabine based 
chemotherapy combined with bevacizumab.
Squamous cell carcinoma whose development is 
strongly associated with smoking habit is the sec-
ond most common histological type of NSCLC in 
the current era. As previously explained, pemetrexed 
has  shown  lower  efficacy  against  squamous  cell 
carcinoma and the increased bleeding risk prevents 
treatment with bevacizumab. In metastatic NSCLC, 
standard chemotherapy regimens, including gemcit-
abine/CDDP, still remain the standard treatment for 
patients with squamous-cell carcinoma.
More  recently,  the  TORCH  trial  was  conducted 
in  patients  with  unselected  NSCLC.  This  was  a 
phase III trial to investigate the efficacy of erlotinib 
as  first-line  therapy  administered  until  progression 
followed  by  gemcitabine/CDDP,  which  compared 
gemicitabine/CDDP for 6 cycles followed at progres-
sion by   erlotinib.28 The first planned interim analysis 
was    performed  with  blinded  data  after  340  deaths 
and a median follow-up of 8.3 months. An indepen-
dent  Data  Monitoring  Committee  recommended 
Table 3. Results of AvAiL trial.
OS (months) PFS (months) Response rate (%)
Gemcitabine/CDDP/  
bevacizumab (7.5 mg/kg) HR (95% CI)
13.6 6.7 34.1
0.92 (0.77–1.10) 0.75 (0.62–0.91)
Gemcitabine/CDDP/  
bevacizumab (15 mg/kg) HR (95% CI)
13.4 6.5 30.4
1.02 (0.85–1.22) 0.82 (0.68–0.98)
Gemcitabine/CDDP 13.1 6.1 20.1Hayashi et al
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early  termination,  because  the  boundary  of  study 
interruption for inferiority was crossed. The OS (8.5 
versus 12.0 months, HR: 1.40; 95% CI: 1.13–1.73) 
and PFS (2.2 versus 5.7 months) in the arm with erlo-
tinib as first-line therapy were inferior compared with 
those in the standard arm. Analysis of subgroups also 
showed that the HR of deaths for non-adenocarcinoma 
(squamous, large-cell carcinoma or NOS) in 44.5% 
patients was 1.09 (95% CI: 0.82–1.45). In a previous 
phase III trial, erlotinib prolonged survival after first-
line treatment and survival benefit was also observed 
in squamous-cell carcinoma.29 However, the result of 
the TORCH trial indicated that EGFR-TKIs was not 
recommended  for  first-line  chemotherapy  for  unse-
lected histology of NSCLC, including squamous-cell 
carcinoma.
Monotherapy of Gemcitabine  
for Elderly or Unfit Patients
More than half of patients with NSCLC were 65 years 
old or older and approximately 30% to 40% of the cases 
were older than 70 years.30 Increasing age is closely 
associated with deterioration of organ function and drug 
pharmacokinetics.  Furthermore,  advanced  NSCLC 
patients older than 70 years often present co-  morbidities, 
which affect functional status, general health and tumor 
symptoms,  and  have  a  poor  PS.  Therefore,  single-
agent chemotherapy used to be the first approach to 
be tested. The Elderly Lung Cancer Vinorelbine Ital-
ian study (ELVIS study), which was the first phase III 
randomized trial done in elderly patients with advanced 
NSCLC, demonstrated that mono-chemotherapy with 
vinorelbine improved survival and quality of life com-
pared to best supportive care (median OS; 6.5 months 
versus 4.8 months, P = 0.03).31 Several phase II trials 
specifically have been designed for elderly patients to 
confirm the role of gemcitabine, because of its low tox-
icity profile. In patients over 70 years old, gemcitabine 
yielded overall response rates of 18%–38% and median 
OS of 6.8–9 months with acceptable toxicity.32
The activity of gemcitabine in combination with 
other agents has also been investigated. Above all, the 
combination of gemcitabine and vinorelbine has been 
one of the most extensively studied non-platinum based 
combinations. However, a large randomized phase III 
trial which accrued about 700 elderly patients showed 
that  the  gemcitabine/vinorelbine  combination  was 
not  more  effective  than  single-agent  chemotherapy 
with  vinorelbine  or  gemcitabine.33  No  statistically 
  significant difference was observed among treatment 
arms from the viewpoints of response rate, PFS, OS 
and quality of life. Median OS was 36, 28 and 30 weeks 
for vinorelbine, gemcitabine and their combination, 
respectively (HR: 1.17; 95% CI: 0.95–1.44   comparing 
with vinorelbine, HR: 1.06; 95% CI: 0.86–1.29 versus 
treatment with gemcitabine).
More recently, weekly paclitaxel/CBDCA was com-
pared with single agent chemotherapy in the context of a 
randomized phase III trial that involved elderly NSCLC 
patients.34 Patients aged 70 to 89 years old, PS 0–2 and 
previously untreated Stage III or IV were randomized to 
receive either paclitaxel/CBDCA (paclitaxel: 90 mg/m2 
on days 1, 8 and 15, CBDCA : AUC 6 on day 1, every 
4 weeks) or single-agent chemotherapy (either gemcit-
abine: 1150 mg/m2, or vinorelbine: 30 mg/m2 on days 1 
and 8, every three weeks). Patients of both arms were 
treated with erlotinib after failure of the initial treatment. 
The planned sample size was 522 patients, however, the 
trial was prematurely closed after randomization of 451 
patients when the second planned analysis showed that 
the reference arm was beneficial. A median OS of 10.3 
for  paclitaxel/CBDCA  was  significantly  longer  than 
that of 6.2 months for single-agent chemotherapy (HR: 
0.64, 95% CI: 0.52–0.79, P , 0.0001). Median PFS was 
6.1 and 3.0 months for patients in the doublet arm and 
single chemotherapy arm, respectively (HR: 0.55, 95% 
CI: 0.44–0.70, P , 0.0001). Early death was defined as 
death occurring less than three months from the start of 
treatment and occurred significantly less frequent with 
the combination therapy as compared to the single-agent 
chemotherapy group (17% versus 26%, P = 0.025), how-
ever, more treatment related deaths occurred in combi-
nation with the chemotherapy arm than with the control 
arm (6.6% versus 1.8%, P = 0.035).
Platinum-based chemotherapy is currently recom-
mended  as  the  standard  approach  for  patients  with 
advanced NSCLC if they can tolerate it. This was the 
first prospective phase III trial to investigate the repro-
ducibility of this benefit even in elderly patients. The 
advantage of platinum-based chemotherapy in terms of 
OS was demonstrated; however, it must be noted that 
paclitaxel/CBDCA was associated with   significantly 
increased  toxicity  of  chemotherapy.  Therefore, 
  single-agent  chemotherapy,  such  as  gemcitabine  or 
vinorelbine, should still be considered as a reasonable 
treatment choice for unfit elderly. As a problem to be Review of gemcitabine efficacy in advanced NSCLC: subgroup of histology
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solved in the future, many efforts will be necessary to 
identify the elderly patients who can and those who 
cannot tolerate platinum-based doublet chemotherapy.
It is unclear whether the outcome will be different 
according to histological subtype, because so far no 
examinations have been performed in elderly or unfit 
patients with advanced NSCLC.
Conclusion
At  present,  most  clinicians  may  consider  pem-
etrexed/CDDP  and  bevacizumab  containing  regi-
mens (with either paclitaxel/CBDCA or gemcitabine/
CDDP) that seem to be excellent for patients with non-
squamous-cell histology of NSCLC. The evaluation 
of treatment selection for patients with non-squamous 
histology must consider both the efficacy and safety 
profiles of these regimens. However, the information 
on gemcitabine regarding treatment of non squamous-
cell histology of NSCLC is limited. On the other hand, 
as for squamous cell carcinoma, gemcitabine-CDDP 
still remains one of the most effective regimens for 
first-line  therapy.  In  elderly  patients,  although  sur-
vival after platinum-based chemotherapy (paclitaxel/
CBDCA) was demonstrated in a recent phase III trial, 
mono-agent  chemotherapy,  such  as  gemcitabine  or 
vinorelbine,  remains  the  treatment  option  for  unfit 
elderly. To our knowledge, with respect to ethics and 
sex of patients, no precise data for differences of effi-
cacy and toxicity has been demonstrated.
This review showed the current status of NSCLC 
treatment and the impact of histology on the clini-
cal outcome of advanced NSCLC. Although, in late 
years, treatment response depending on the histologi-
cal type is gaining attention due to the appearance of 
pemetrexed and bevacizumab, there have been very 
few studies on the response to gemcitabine by differ-
ence histological types of NSCLC. Is the difference of 
the histological type really as important as expected? 
When clinicians choose appropriate   treatment accord-
ing  to  the  histological  type,  some  problems  will 
arise. At first it is not easy to accurately distinguish 
non-squamous from squamous type by pathological 
  examination. It is more difficult for poorly differenti-
ated carcinoma in particular, and it is often difficult for 
experienced pathologists to achieve consensus regard-
ing a definite diagnosis. Therefore, a diagnostic tool 
that can allow a definite distinction of squamous carci-
noma from non-squamous carcinoma is required.
Moreover, the only agent that showed a different 
effect  on  non-squamous  carcinoma  and  squamous 
carcinoma was pemetrexed, but, pemetrexed is not 
invalidity in squamous cases at all. It is imagined that 
biomarker that provides for the effect of pemetrexed 
may exist surely.
At present, when the most appropriate chemother-
apeutic regimen for an individual is being sought, not 
only the use of molecular markers but also histologi-
cal types will play key roles when seeking personal-
ized treatment for patients with advanced NSCLC. In 
the old days, morphology was regarded as the most 
important factor, but it seems that a therapy based on 
molecular biology will become more important in the 
near future. Therefore, specially designed prospec-
tive randomized trials and translational studies are 
warranted to find useful predictors of the efficacy of 
every chemotherapeutic agent.
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